Changes and clinical significance of PD-1 and PD-Ls in mononuclear cells in patients with idiopathic thrombocytopenic purpura

doi:10.3877/cma.j.issn.2095-5820.2018.04.003

Abstract

Abstract:

Objective

To investigate the changes and clinical significance of programmed death factor (PD-1) and its ligand (PD-Ls) in peripheral blood mononuclear cells of patients with idiopathic thrombocytopenic purpura (ITP).

Methods

The expressions of T lymphocytes and monocyte supramolecular molecules (CD273, CD274 and CD279) in peripheral blood of 26 adult patients with acute ITP were detected by flow cytometry before treatment, and 3 months, 6 months and one year after treatment. Correlation of each indice and variance tests of random block was analyzed.

Results

Compared with ITP patients before treatment, the expression of PD-Ls in monocytes decreased significantly at 3 months, 6 months and one year after treatment (P<0.05), while the expression of PD-1 in CD8⁺ T lymphocytes increased significantly at 6 months and one year after treatment (P<0.05). Correlation analysis showed that the expression of PD-Ls in monocytes was positively correlated with PD-1 expression in CD8⁺ T lymphocytes (P<0.01).

Conclusion

The platelet count in patients with ITP were correlated with the expression of PD-1 and PD-Ls in mononuclear cells, which proved that PD-1 and PD-Ls could be used as a dynamic index to observe the therapeutic effect of ITP.

Key words: Idiopathic thrombocytopenic purpura, Programmed death factor-1, Ligand

Guozhong Zhou, Hongqiang Luo, Huiyu Wang. Changes and clinical significance of PD-1 and PD-Ls in mononuclear cells in patients with idiopathic thrombocytopenic purpura[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2018, 06(04): 204-207.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcsysgldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5820.2018.04.003

https://zhlcsysgldzzz.cma-cmc.com.cn/EN/Y2018/V06/I04/204

Figures/Tables 2

References 20

[1]	王春燕，朱效娟，侯明，等. 大剂量地塞米松对特发性血小板减少性紫癜患者B细胞活化因子及调节性T细胞的影响[J]. 中华血液学杂志, 2010,31(3):164-167.
[2]	Riley JL. PD-1 signaling in primary T cells[J]. Immunol Rev, 2009,229(1):114-125.
[3]	Folkl A,Bienzle D. Structure and function of program-med death(PD)molecules[J]. Vet Immunol Immunopathol, 2010,134(1-2):33-38.
[4]	Dai S,Jia R Zhang X, et al. The PD-1/PD-Ls pathway and autoimmune diseases[J]. Cell Immunol, 2014,290(1):72-79.
[5]	Moll M,Kuylenstierna C,Gonzalez VD, et al. Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection[J]. Eur J Immunol, 2009,39(3):902-911.
[6]	Rodeghiero F,Stasi R,Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group[J]. Blood, 2009,113(11):2386-2393.
[7]	Zamani MR,Aslani S,Salmaninejad A, et al. PD-1/PD-L and autoimmunity: A growing relationship[J]. Cellular Immunol, 2016,310:27-41.
[8]	中华医学会血液学分会止血与血栓学组. 成人原发免疫性血小板减少症诊断与治疗中国专家共识(2016年版)[J]. 中华血液学杂志, 2016,37(2):89-93.
[9]	Rodeghiero F,Stasi R,Gernsheimer T, et al. Standardization of terminology definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group[J]. Blood, 2009,113(11):2386-2393.
[10]	侯明. 成人ITP诊断和治疗专家共识[J]. 中华血液学杂志, 2009,30(9):574-575.
[11]	郭莹，瞿文，王一浩，等. 共刺激信号分子对免疫性血小板减少症患者B淋巴细胞免疫功能的影响[J]. 中国实验血液学杂志, 2016,24(4):1110-1115.
[12]	翟菊萍，何杨，杨炳华. 免疫失耐受在ITP自身抗体产生机制中的研究进展[J]. 中华微生物学和免疫学杂志, 2016,36(10):790-794.
[13]	Wang L,Han R,Hancock WW. Programmed cell death 1 (PD-1) and its ligand PD-L1 are required for allograft tolerance[J]. Eur J Immunol, 2007,37(10):2983-2990.
[14]	周国忠，钟永根，孙荷，等. 泼尼松对免疫性血小板减少性紫癜患者T细胞和NK细胞凋亡信号通路的影响[J]. 中华全科医学, 2016,14(2):273-274.
[15]	Folkl A,Bienzle D. Structure and function of programmed death (PD) molecules[J]. Vet Immunol Immunopathol, 2010,134(1-2):33-38.
[16]	周璞，侯明. 特发性血小板减少性紫癜的细胞免疫机制[J]. 中华血液学杂志, 2003,24(9):502-504.
[17]	Jachetti E,Caputo S,Mazzoleni S, et al. Tenascin-C protects cancer stem-like cells from immune surveillance by arresting T-cell activation[J]. Cancer Res, 2015,75(10):2095-2108.
[18]	Malhotra D,Linehan JL,Dileepan T, et al. Tolerance is established in polyclonal CD4(＋) T cell by distinct mechanisms, according to self-peptide expression patterns[J]. Nat Immunol, 2016,17(2):187-195.
[19]	Subburayalu J,Wilde B. ″Programmed-cell-death″-Protein 1 (PD-1/CD279)[J]. Der Nephrologe, 2016,11(1):70-72.
[20]	刘文宾，吴迪炯，叶宝东，等. 重组人血小板生成素治疗继发性免疫性血小板减少症的临床观察[J]. 中华全科医学, 2016,14(3):349-351.

组别	A	B	C	D
血小板浓度（×10⁹/L）	69.43±55.66	117.63±96.14^a	72.64±34.85	83.00±54.37
CD4^＋	35.17±29.82	14.01±10.79^a	21.69±11.21	24.82±17.50
CD8^＋	27.95±19.53	16.13±12.66^a	19.72±10.21	21.65±11.40
CD14^＋	9.58±5.13	7.40±5.66	5.71±2.21^a	7.83±5.31
CD14^＋CD273^＋	1.53±0.71	0.35±0.16^a	0.46±0.22^a	0.50±0.28^a
CD14^＋C274^＋	1.55±1.24	0.13±0.12^a	0.35±0.19^a	0.59±0.22^a
CD4^＋CD279^＋	2.07±1.26	0.26±0.19^a	0.73±0.56^a	1.52±1.20^bc
CD8^＋CD279^＋	3.97±1.69	0.48±0.28^a	4.09±1.64^b	4.93±2.32^b

组别	A	B	C	D
血小板浓度（×10⁹/L）	69.43±55.66	117.63±96.14^a	72.64±34.85	83.00±54.37
CD4^＋	35.17±29.82	14.01±10.79^a	21.69±11.21	24.82±17.50
CD8^＋	27.95±19.53	16.13±12.66^a	19.72±10.21	21.65±11.40
CD14^＋	9.58±5.13	7.40±5.66	5.71±2.21^a	7.83±5.31
CD14^＋CD273^＋	1.53±0.71	0.35±0.16^a	0.46±0.22^a	0.50±0.28^a
CD14^＋C274^＋	1.55±1.24	0.13±0.12^a	0.35±0.19^a	0.59±0.22^a
CD4^＋CD279^＋	2.07±1.26	0.26±0.19^a	0.73±0.56^a	1.52±1.20^bc
CD8^＋CD279^＋	3.97±1.69	0.48±0.28^a	4.09±1.64^b	4.93±2.32^b

?	血小板	CD14^＋CD274^＋	CD4^＋CD279^＋	CD14^＋CD273^＋	CD8^＋CD279^＋	CD14^＋	CD4^＋	CD8^＋
血小板	1.000	-0.246	-0.073	-0.242	-0.138	-0.135	-0.282	-0.197
CD14^＋CD274^＋	-0.246	1.000	0.042	0.912^b	0.546^b	0.108	0.367^a	0.391^a
CD4^＋CD279^＋	-0.073	0.042	1.000	-0.046	0.357^b	-0.061	-0.275	-0.101
CD14^＋CD273^＋	-0.242	0.912^b	-0.046	1.000	0.607^b	0.227	0.527^b	0.444^b
CD8^＋CD279^＋	-0.138	0.546^b	0.357^a	0.607^b	1.000	-0.022	0.172	0.067
CD14^＋	-0.135	0.108	-0.061	0.227	-0.022	1.000	0.443^b	0.458^b
CD4^＋	-0.282	0.367^a	-0.275	0.527^b	0.172	0.443^b	1.000	0.700^b
CD8^＋	-0.197	0.391^a	-0.101	0.444^b	0.067	0.458^b	0.700^b	1.000

?	血小板	CD14^＋CD274^＋	CD4^＋CD279^＋	CD14^＋CD273^＋	CD8^＋CD279^＋	CD14^＋	CD4^＋	CD8^＋
血小板	1.000	-0.246	-0.073	-0.242	-0.138	-0.135	-0.282	-0.197
CD14^＋CD274^＋	-0.246	1.000	0.042	0.912^b	0.546^b	0.108	0.367^a	0.391^a
CD4^＋CD279^＋	-0.073	0.042	1.000	-0.046	0.357^b	-0.061	-0.275	-0.101
CD14^＋CD273^＋	-0.242	0.912^b	-0.046	1.000	0.607^b	0.227	0.527^b	0.444^b
CD8^＋CD279^＋	-0.138	0.546^b	0.357^a	0.607^b	1.000	-0.022	0.172	0.067
CD14^＋	-0.135	0.108	-0.061	0.227	-0.022	1.000	0.443^b	0.458^b
CD4^＋	-0.282	0.367^a	-0.275	0.527^b	0.172	0.443^b	1.000	0.700^b
CD8^＋	-0.197	0.391^a	-0.101	0.444^b	0.067	0.458^b	0.700^b	1.000

Please choose a citation manager

Content to export